BioXcel Therapeutics (BTAI) Misses Q2 EPS by 15c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. ABBV
4. LITE
5. CL
6. LYB
7. TFII
8. NVT
9. SPY
10. AAPL

Go back to BioXcel Therapeutics (BTAI) Misses Q2 EPS by 15c

BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational Highlights

August 9, 2022 7:00 AM EDT

Commercially launched IGALMI (dexmedetomidine) sublingual film for the acute treatment of agitation in bipolar I or II disorder and schizophrenia in adult patients

SERENITY III pivotal trial evaluating at-home use of BXCL501 for the acute treatment of agitation in bipolar and schizophrenia patients planned to initiate in 2H 2022 following recent Type B meeting with FDA

Top-line data from TRANQUILITY II pivotal trial for agitation associated with Alzheimers disease expected in 1H 2023; TRANQUILITY III enrollment initiating in 2H 2022

Top-line results from ongoing Phase 1 Major Depressive... More